IDEA logo header

020 392 10201

info@IDEAregulatory.com
  • Home
  • Services
  • About idea
  • Blog
  • Contact us
Linkedin

Home » Applying for Orphan Drug Designation: Should the USA always be your first regulatory target?

Applying for Orphan Drug Designation: Should the USA always be your first regulatory target?

October 21, 2017 | by admin

In this article we examine 5 common myths surrounding FDA vs. EMA applications for Orphan Drug Designation applications.

Download PDF: Microsoft Word – ODD – Should the USA always be first regulatory target

Footer

Linkedin

Latest news

MHRA taps into expertise to drive innovation for rare diseases in UK

The biggest mistakes when applying for clinical trial approval in the EU for a rare disease

Comparing rare disease applications in the EU and the US

Links

  • Disclaimer
  • Data privacy statement
  • Impressum
  • FAQ

Copyright IDEA Regulatory 2014 - 2025. All rights reserved.

  • About idea
  • Contact us
  • Sitemap
Call us
Send us an email